MARKET

ZYNE

ZYNE

Zynerba Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.38
+0.27
+4.42%
Closed 16:41 11/15 EST
OPEN
6.14
PREV CLOSE
6.11
HIGH
6.51
LOW
6.00
VOLUME
527.61K
TURNOVER
--
52 WEEK HIGH
16.47
52 WEEK LOW
2.750
MARKET CAP
148.00M
P/E (TTM)
-4.2556
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ZYNE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ZYNE News

  • SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zynerba Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline- ZYNE
  • ACCESSWIRE.1d ago
  • Cannabis Stock Gainers And Losers From November 15, 2019
  • Benzinga.2d ago
  • Zynerba Pharmaceuticals Enters Oversold Territory
  • Zacks.2d ago
  • Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE)
  • ACCESSWIRE.2d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About ZYNE

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
More

Webull offers Zynerba Pharmaceuticals Inc (ZYNE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.